Nanopath Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $29.9M

  • Investors
  • 20

Nanopath General Information

Description

Developer of a molecular diagnostic platform designed to enable point-of-care disease diagnosis. The company's technology eliminates the need for nucleic acid amplification and supports multiplexed detection, enabling patients and providers to access actionable diagnostic results within standard office visits for improved healthcare outcomes.

Contact Information

Formerly Known As
Nanopathdx
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 750 Main Street
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 750 Main Street
  • Cambridge, MA 02139
  • United States
+1 (617)

Nanopath Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nanopath Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
18. Later Stage VC (Series B) 10-Nov-2026 $29.9M Completed Product Development
17. Grant 10-Nov-2026 Completed Product Development
16. Grant 30-Jun-2025 Completed Product Development
15. Later Stage VC 06-Feb-2025 Completed Product Development
14. Grant 01-Sep-2024 Completed Product Development
13. Grant 01-Mar-2024 Completed Product Development
12. Grant 01-Sep-2023 Completed Product Development
11. Accelerator/Incubator 01-Apr-2022 Completed Product Development
10. Grant 24-Apr-2023 $10K $11M Completed Product Development
9. Accelerator/Incubator 22-Dec-2022 $11M Completed Product Development
To view Nanopath’s complete valuation and funding history, request access »

Nanopath Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 3
Series B 2
Series B 1
Series A 2
Series A 1 960,984 $0.000010 8% $1.04 $1.04 1x $1.04 5.66%
Series A 2,495,940 $0.000010 8% $4.01 $4.01 1x $4.01 14.71%
To view Nanopath’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nanopath Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a molecular diagnostic platform designed to enable point-of-care disease diagnosis. The company's technolog
Diagnostic Equipment
Cambridge, MA
29 As of 2026

Oxford, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nanopath Competitors (1)

One of Nanopath’s competitors is Oxford Nanopore Technologies, a Formerly VC-backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxford Nanopore Technologies Formerly VC-backed Oxford, United Kingdom
You’re viewing 1 of 1 competitors. Get the full list »

Nanopath Patents

Nanopath Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026024986-A1 Homogenous deposition of colloidal nanoparticles Pending 26-Jul-2024
EP-4540609-A2 Multiplexed pathogen detection using nanoplasmonic sensor for human papillomavirus Pending 16-Jun-2022
EP-4540609-A4 Multiplexed pathogen detection using nanoplasmonic sensor for human papillomavirus Pending 16-Jun-2022
US-20250361572-A1 Multiplexed pathogen detection using nanoplasmonic sensor for human papillomavirus Pending 16-Jun-2022
WO-2023245145-A2 Multiplexed pathogen detection using nanoplasmonic sensor for human papillomavirus Inactive 16-Jun-2022 C12Q1/708
To view Nanopath’s complete patent history, request access »

Nanopath Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nanopath Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
Elderberry Ventures Venture Capital Minority
Labcorp Venture Fund Corporate Venture Capital Minority
nCourage Investment Group Angel Group Minority
MassVentures Venture Capital Minority
Medical Device Innovation Consortium Corporation
You’re viewing 5 of 20 investors. Get the full list »

Nanopath FAQs

  • When was Nanopath founded?

    Nanopath was founded in 2019.

  • Where is Nanopath headquartered?

    Nanopath is headquartered in Cambridge, MA.

  • What is the size of Nanopath?

    Nanopath has 29 total employees.

  • What industry is Nanopath in?

    Nanopath’s primary industry is Diagnostic Equipment.

  • Is Nanopath a private or public company?

    Nanopath is a Private company.

  • What is the current valuation of Nanopath?

    The current valuation of Nanopath is .

  • What is Nanopath’s current revenue?

    The current revenue for Nanopath is .

  • How much funding has Nanopath raised over time?

    Nanopath has raised $46.2M.

  • Who are Nanopath’s investors?

    Elderberry Ventures, Labcorp Venture Fund, nCourage Investment Group, MassVentures, and Medical Device Innovation Consortium are 5 of 20 investors who have invested in Nanopath.

  • Who are Nanopath’s competitors?

    Oxford Nanopore Technologies is a competitor of Nanopath.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process